Abstract
Aim
To assess the evidence supporting early antibiotic treatment in asymptomatic cystic fibrosis (CF) patients colonised by Pseudomonas aeruginosa (PA).
Methods
We carried out a computerised (Medline, Embase) and hand search of journals for suitable publications. All English-language clinical studies regarding the efficacy of early antibiotic treatment on PA colonisation in asymptomatic patients were considered. Each eligible publications fitting these criteria were assessed for the following outcome measures: frequency of positive PA cultures; serum level of precipitating antibodies; lung function; survival; number of hospitalisations; adverse effects and resistance to antibiotics.
Results
Of the 11 studies eventually considered, 3 were randomised—2 versus placebo— and 8 were cohort studies—2 of which had historical controls. Overall, 309 patients (population range 7–91 patients) were recruited. There was a high variability between the individual studies for age, outcome measures, duration of follow-up (1 to 44 months) and treatment (three studies used only aerosol tobramycin, one colistin, four aerosol colistin plus oral ciprofloxacin, one used intravenous treatment and two miscellaneous therapy). An overall evaluation indicated that early antibiotic treatment can reduce the number of positive cultures and the anti-PA antibody titre. In one study, FEV1 was better in the treated group (oral ciprofloxacin and nebulised colistin) than in historical controls, while in one placebo-controlled trial, no effect on lung function was shown after 1 year of tobramycin inhalation. Collateral effects and bacterial resistance were not increased. The short follow-up did not allow definite conclusions with regard to the long-term progression of respiratory insufficiency or survival.
Conclusions
Evidence was found that antibiotic treatment can reduce the rate of positive cultures and of anti-PA antibody titres in asymptomatic CF patients with newly isolated PA. Different therapeutic options have not been directly compared: a multi-centre comparative study needs to be carried out.
Similar content being viewed by others
References
FitzSimmons SC (1993) The changing epidemiology of cystic fibrosis. J Pediatr 122:1–9
Cystic fibrosis foundation (2001) Patient registry 2000 (annual report). Cystic Fibrosis Foundation, Bethesda
Conese M, Assael BM (2001) Bacterial infections and inflammation in the lungs of cystic fibrosis patients. Pediatr Infect Dis J 20:207–213
Kerem E (1997) The role of Pseudomonas aeruginosa in the pathogenesis of lung disease in cystic fibrosis: more questions than answers. Pediatr Pulmonol Suppl 16:265–266
Kerem E, Corey M, Gold R, Levison H (1990) Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 116:714–719
Aebi C, Bracher R, Liechti-Gallati S, Tschappeler H, Rudeberg A, Kraemer R (1995) The age at onset of chronic Pseudomonas aeruginosa colonization in cystic fibrosis: prognostic significance. Eur J Pediatr 154[Suppl 4]:S69–S73
Winnie GB, Cowan RG (1991) Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlation between anti-Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr Pulmonol 10:91–100
Pamukcu A, Bush A, Buchdahl R (1995) Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 19:10–15
Kosorok MR, Zeng L, West SHE et al (2001) Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 32:277–287
Nixon GM, Armstrong DS, Carzino R et al (2001) Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 138:699–704
Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL (2002) Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34:91–100
Borsje P, de Jongste JC, Mouton JW, Tiddens HAWM (2000) Aerosol therapy in cystic fibrosis: a survey of 54 CF centers. Pediatr Pulmonol 30:368–376
Valerius NH, Koch C, Hoiby N (1991) Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338:725–726
Vazquez C, Municio M, Corera M, Gaztelurrutia L, Sojo A, Vitoria JC (1993) Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Acta Paediatr 82:308–309
Frederiksen B, Koch C, Hoiby N (1997) Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23:330–335
Wiesemann HG, Steinkamp G, Ratjen F et al (1998) Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 25:88–92
Griese M, Muller I, Reinhardt D (2002) Eradication of initial Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Eur J Med Res 7:79–80
Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M et al (2003) Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 167:841–849
Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH (1985) Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet 1:865
Steinkamp G, Tummler B, Malottke R, von der Hardt H (1989) Treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Arch Dis Child 64:1022–1028
Ratjen F, Doring G, Nilolaizik WH (2001) Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 358:983–984
Taccetti G, Repetto T, Procopio E, Farina S, Campana S (2002) Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients. Lancet 359:625–626
Munck A, Bonacorsi S, Mariani-Kurkdjian P, Lebourgeois M, Gerardin M, Brahimi N, Navarro J, Bingen E (2001) Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonisation. Pediatr Pulmonol 32:288–292
Doring G, Conway SP, Heijerman HGM, Hodson ME, Hoiby N, Smyth A, Touw DJ for the Consensus Committee (2000) Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16:749–767
Ratjen F, Doring G (2003) Cystic fibrosis. Lancet 361:681–689
Lang AB, Schaad UB, Rudeberg A et al (1995) Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunisation on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatr 127:711–717
Rabin HR, Wohl ME (1997) The preservation of function: treatment of new acquisition of a pathogen. Pediatr Pulmonol 23:323–324
Spilker B (1991) Guide to clinical trials. New York: Raven:35–36
Conway SP, Pond MN, Hamnett T, Watson A (1996). Compliance with treatment in adult patients with cystic fibrosis. Thorax 51:29–33
Conway SP (1999) Evidence for using nebulised antibiotics in cystic fibrosis. Arch Dis Child 80:307–309
Burns JL, Van Dalfsen JM, Shawar RM et al (1999) Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179:1190–1196
Cheer SM, Waugh J, Noble S (2003) Inhaled tobramycin (TOBI). A review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 63:2501–2520
Anonymous (2001) TOBI prescribing information. CHIRON Corporation, Emeryville, CA
Ramsey BW, Boat TF (1994) Outcome measures for clinical trials in cystic fibrosis. J Pediatr 124:177–192
Morgan WJ, Butler SM, Johnson CA et al (1999) Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 28:231–241
Cheng K, Smyth RL, Motley J, O’Hea U, Ashby D (2000) Randomized controlled trials in cystic fibrosis (1966–1997) categorized by time, design, and intervention. Pediatr Pulmonol 29:1–7
Acknowledgement
The authors wish to thank Judy Moss for the revision of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marchetti, F., Giglio, L., Candusso, M. et al. Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature. Eur J Clin Pharmacol 60, 67–74 (2004). https://doi.org/10.1007/s00228-004-0735-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-004-0735-2